Research Triangle Park, NC (December 15, 2004) – Study results published today in the journal Movement Disorders show that Requipâ(ropinirole HCl) Tablets effectively treats the symptoms of primary ...
COLUMBUS, Ohio, May 5 Roxane Laboratories, Inc. announcedtoday the approval of its Abbreviated New Drug Application (ANDA) forRopinirole Hydrochloride Tablets, 0.25mg ...
Dr. Reddy’s Laboratories announced that it has launched Ropinirole Hydrochloride XR extended-release tablets - 2 mg, 4 mg, 6 mg, 8mg, and 12 mg - a bioequivalent generic version of REQUIP XL tablets ...
Drug discontinued-text Requip and Requip XL are non-ergot dopamine agonists indicated for the treatment of Parkinson disease. Requip and Requip XL are non-ergot dopamine agonists indicated for the ...
Actavis hasreceived FDA approval for Ropinirole Extended-Release Tablets, 2mg, 4mg, 6mg,8mg, and 12mg, a generic equivalent to Requip XL (GlaxoSmithKline).Distribution of the product has commenced.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback